Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Equity (2022 - 2025)

Historic Return on Equity for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to 0.29%.

  • Entrada Therapeutics' Return on Equity fell 4200.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year decrease of 4200.0%. This contributed to the annual value of 0.2% for FY2024, which is 2200.0% up from last year.
  • Per Entrada Therapeutics' latest filing, its Return on Equity stood at 0.29% for Q3 2025, which was down 4200.0% from 0.18% recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Return on Equity high stood at 0.3% for Q2 2024, and its period low was 0.42% during Q4 2022.
  • Its 4-year average for Return on Equity is 0.09%, with a median of 0.06% in 2023.
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 6800bps in 2024, then crashed by -4800bps in 2025.
  • Entrada Therapeutics' Return on Equity (Quarter) stood at 0.42% in 2022, then soared by 94bps to 0.03% in 2023, then surged by 664bps to 0.15% in 2024, then tumbled by -287bps to 0.29% in 2025.
  • Its Return on Equity was 0.29% in Q3 2025, compared to 0.18% in Q2 2025 and 0.06% in Q1 2025.